Quick Facts: Therapeutic Domains

• Management of certain respiratory tract infections.
• Treatment of specific skin and soft tissue infections.
• Used for conditions affecting the urinary tract.
• May be administered for certain cases of bacterial otitis media (ear infection).

Infectocef is indicated for the treatment of various infections caused by susceptible strains of bacteria. The medication assists in managing conditions affecting several body systems, including respiratory, integumentary, and urinary systems.

The authorized uses typically encompass the management of certain lower respiratory tract infections, such as pneumonia, when caused by identified susceptible bacteria. It is also utilized in managing acute bacterial exacerbations of chronic bronchitis. Additionally, Infectocef is indicated for certain uncomplicated skin and skin-structure infections, aiding in the resolution of the bacterial component of these conditions. It also has a role in the treatment of specific infections of the urinary tract, including complicated and uncomplicated presentations.

Furthermore, Infectocef may be used in the treatment of acute bacterial otitis media (an ear infection) in pediatric patients and other approved populations when deemed medically appropriate. The determination to use this medication must be based on the pathogen's confirmed susceptibility and the patient's specific clinical presentation.

Who Can and Cannot Use Infectocef (Cefaclor)

Official regulatory information defines specific population eligibility rules for using Infectocef, based strictly on medical history and age criteria.

Contraindicated and Ineligible Populations

Infectocef is contraindicated and must not be used by patients with a known allergy or severe hypersensitivity reaction to cefaclor or to any other cephalosporin antibiotic. Caution is also warranted for individuals with a history of severe penicillin allergy due to the potential for cross-reactivity.

Use is formally not established and therefore generally ineligible for infants younger than one month of age. Furthermore, the extended-release tablet formulation is not established for children under 16 years of age.

---

Restricted and Conditional Use

Population Group	Regulatory Status
Renal Impairment	Use requires caution in patients with markedly impaired renal function.
Gastrointestinal History	Use requires caution in individuals with a history of colitis or other gastrointestinal disease.
Pregnancy and Lactation	Use is only advised if clearly needed; caution is recommended for both pregnant and nursing women.

Adults and pediatric patients one month of age and older are generally eligible for the immediate-release forms of Infectocef, provided no contraindications exist.

The officially documented interaction profile for Infectocef (Cefaclor) focuses primarily on pharmacokinetic changes and specific pharmacodynamic effects, as described in regulatory labeling.

Drug-Drug and Substance Interactions

Interaction Category	Official Regulatory Outcome
Altered Clearance	Co-administration with Probenecid is officially documented to decrease the drug's renal tubular secretion. This pharmacokinetic interaction results in increased and prolonged serum concentrations of Cefaclor.
Anticoagulant Effect	Concomitant use with Oral Anticoagulants (such as Warfarin) has been associated with an increased anticoagulant effect and, in some cases, an increase in prothrombin time.
Altered Absorption	Aluminum- or Magnesium-containing Antacids diminish the extent of Cefaclor absorption. The regulatory restriction requires that these antacids must be administered at least one hour apart from the Cefaclor immediate-release forms.

Food and Testing Constraints

The presence of food decreases the peak plasma concentration (mathbfCmax) and delays the time to peak concentration (mathbfTmax) for the immediate-release capsule, though the total absorption (AUC) remains unchanged. Additionally, the use of Cefaclor may cause a false-positive reaction for glucose during specific urine tests (those using Benedict's or Fehling's solutions or Clinitest tablets). Caution regarding potential accumulation is noted for patients with renal impairment, particularly when combined with clearance-inhibiting agents.

Infectocef functions through the irreversible inhibition of key bacterial enzymes known as penicillin-binding proteins (PBPs). These PBPs are critical transpeptidases responsible for the final cross-linking step in the construction of the bacterial cell wall's structural layer, the peptidoglycan.

Upon binding covalently to PBPs, Infectocef prevents the formation of a structurally intact cell wall. This specific pathway blockade immediately compromises the integrity of the bacteria, leading to a loss of osmotic stability. The subsequent mechanistic cascade results in the physical breakdown and elimination of the susceptible bacterial cells (lysis).

A secondary mechanistic domain involves the drug's inherent resistance to certain bacterial beta-lactamase enzymes, a common microbial defense. By avoiding this enzymatic hydrolysis, Infectocef maintains a sufficient concentration of active molecules to effectively engage and inhibit its PBP targets, thereby facilitating the sustained cell wall inhibition required for its full pharmacodynamic effect.

Official Administration Guidelines for Infectocef (Cefaclor)

Infectocef is an orally administered antibiotic with specific usage instructions depending on the chosen formulation. The total duration of therapy is typically 7 to 10 days, but must be a minimum of 10 days when treating infections caused by beta-hemolytic streptococci. Completing the entire prescribed course is essential to proper use.

---

Dosing and Frequency

The standard adult dosing for the immediate-release (IR) forms (capsule or oral suspension) is usually 250 mg taken every 8 hours (three times daily). For more severe infections, this dose is typically increased to 500 mg taken every 8 hours.

The extended-release (ER) tablet is administered on a twice-daily schedule (every 12 hours), with doses typically ranging from 375 mg to 750 mg depending on the approved indication.

---

Administration Instructions

Feature	Instruction
Immediate-Release Forms	May be taken with or without food.
Extended-Release Tablets	Must be taken with a meal and must not be crushed, cut, or chewed.
Oral Suspension	Requires reconstitution with water and must be shaken well before each measured dose is administered.

---

Population-Specific Use

Dosage for pediatric patients is determined by body weight, calculated between 20 mg/kg/day and 40 mg/kg/day, divided into doses taken every 8 or 12 hours, not exceeding 1 g per day. No general adjustment to the adult regimen is typically required for patients with moderately impaired renal function. If a dose is missed, it should be taken as soon as remembered; otherwise, the missed dose should be skipped to resume the regular schedule.

Research evidence / Overview of studies for Infectocef

The evidence for the authorized uses of Infectocef (Cefaclor) is based primarily on clinical research, as documented in official sources. The goal of this research was to explore how symptoms evolved and was to evaluate the measured outcome of pathogen clearance in specific patient groups. This overview describes the research landscape, including what was studied and what remains uncertain, based on regulatory documentation.

---

Evidence for use in Respiratory Tract Infections and Otitis Media

Research was conducted for its use in conditions like pneumonia, acute exacerbations of chronic bronchitis (AECB), and otitis media (ear infection), which are all conditions associated with acute or disruptive episodes. These studies were applied in research contexts involving fluctuating or unstable symptoms, where researchers measured outcomes related to physical discomfort and recovery from the acute illness.

For pneumonia and AECB, the research base includes both Comparative Clinical Trials and Open-Label Trials focused on adult populations. These studies were used in research exploring how symptoms change over time, tracking the resolution of infection signs and the Bacteriological Eradication (elimination of the responsible bacteria). Findings describe patterns observed in the studies related to Clinical Response and the measured rate of pathogen clearance from the respiratory system.

---

Evidence for use in Urinary and Skin Infections

The research examined Infectocef use in studies involving urinary tract infections (UTIs) and uncomplicated skin and skin structure infections (SSSIs).

In research scenarios related to UTIs, Clinical Trials and Bacteriological Evaluation Studies were evaluated in both adult and pediatric populations. These studies monitored outcomes linked to inflammatory or irritative states and focused heavily on achieving Bacteriological Eradication (clearing bacteria from the urine). Follow-up was observed in some studies for up to four weeks to assess long-term clearance.

---

What is Still Uncertain About the Research

Research highlights what is known — and what is still uncertain regarding Infectocef.

Key limitations in the research include the fact that the profile of the measured effects is not established for infants less than one month of age. Furthermore, data for certain groups remain insufficient, and research was observed in some studies to lack robust data establishing its role in the secondary prevention of subsequent conditions (such as rheumatic fever following specific streptococcal infections). This area represents an evidence gap where research is ongoing or data are still emerging.

Key Studies & References Cephalosporins (NIH Bookshelf)

Common questions about Infectocef (FAQ)

Q: Is Infectocef used for viral infections?

Infectocef is an antibiotic intended only to treat infections that are proven or strongly suspected to be caused by bacteria. According to official drug information, this medicine will not be effective against infections caused by viruses, such as the common cold or the flu.

---

Q: Is it normal to feel tired after starting Infectocef?

Regulatory documents mention that some adverse reactions affecting the central nervous system, such as somnolence (sleepiness) or tiredness, are reported, although they occur rarely. Concerns regarding adverse reactions, including unexpected tiredness, should be raised with a healthcare professional.

---

Q: Can Infectocef affect birth control pills?

Information from drug interaction monitoring and regulatory guidance indicates that Infectocef, like other antibiotics in its class, may potentially reduce the effectiveness of oral contraceptives (birth control pills). This effect could increase the risk of an unintended pregnancy or breakthrough bleeding. Individuals using oral contraceptives are generally advised to consult with a healthcare professional regarding the potential for reduced efficacy.

---

Q: Can elderly patients take Infectocef?

Regulatory guidelines indicate that elderly patients (over 65 years old) who have normal kidney function do not typically require dose changes based on age alone. However, official information notes that caution is advised for this population due to the potential for diminished renal function and the risk of neurotoxicity.

---

Q: How long after the last dose of Infectocef is it out of my system?

The drug's reported plasma half-life (the time it takes for the amount of drug in the body to be reduced by half) is short, around 0.5 to 1 hour. Most of the medication is eliminated from the body as unchanged drug through the urine, primarily within about 8 hours after a dose.

---

Q: Is there a generic version of Infectocef available?

Yes, Infectocef contains the active ingredient cefaclor, which is widely available from various manufacturers as a generic medication.

---

Q: Can Infectocef make me feel dizzy or lightheaded?

Dizziness is listed in regulatory documents as a Central Nervous System (CNS) adverse reaction, although it is reported rarely. The potential for this effect is noted in regulatory documents.

---

Q: What should I do if a side effect from Infectocef seems concerning?

The official recommendation is that the decision to discontinue the drug, along with immediately contacting a healthcare provider, should occur if an adverse reaction is suspected. Furthermore, all patients are encouraged to report any suspected side effects to the relevant government drug authority.

---

Q: Can Infectocef make certain chronic conditions worse?

Caution is specifically advised in regulatory information for individuals with a history of gastrointestinal disease, particularly colitis (inflammation of the colon). This is due to the described risk of developing a serious gut condition known as antibiotic-associated pseudomembranous colitis.

---

Q: What does the research say about Infectocef’s use in patients with liver impairment?

Official product information notes that caution is necessary when Infectocef is used in patients with known liver disease, as clinical experience and data are limited in this population. Rare cases of transient hepatitis (temporary liver inflammation) and cholestatic jaundice (a type of yellowing of the skin/eyes) have been reported.

---

Q: What is the official recommendation regarding driving or operating machinery while on Infectocef?

Official advice states that patient caution is warranted when driving or operating machinery. These activities should be approached carefully until the patient understands the drug's individual effect, as it may cause dizziness or tiredness.

How to Store and Dispose of Infectocef (Cefaclor)

Storage Requirements

Solid forms of Cefaclor (capsules, tablets, and dry powder) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and protected from excessive moisture. All forms must be stored in a tightly closed container and kept out of the sight and reach of children.

Reconstituted Suspension Stability

The Cefaclor oral suspension, once mixed, must be stored under refrigeration at 2 C to 8 C (36 F to 46 F) and must not be frozen. The suspension is stable for only 14 days when refrigerated, and any remaining portion must be discarded after this period.

Disposal

Unused or expired Cefaclor should be safely discarded using a drug take-back program. If one is unavailable, the medicine should be mixed with an unappealing substance, such as coffee grounds, sealed in a bag, and then placed in the household trash, following local regulations.